


AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000056	<b>PO-001</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Induction efficacy and safety of upadacitinib for active Crohn’s disease in Japan
C000275	<b>PO-002</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Clinical Outcomes of Upadacitinib in Crohn’s Disease: A Retrospective Observational Study from a Chinese Tertiary Center
C000102	<b>PO-003</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Effectiveness and Safety of Upadacitinib in Refractory Crohn’s Disease Patients: A Multicenter Study from China
C000369	<b>PO-004</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis
C000240	<b>PO-005</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Three Cases of Drug-Induced Lymphocyte Stimulation Test (DLST) Positivity in Ulcerative Colitis Patients Treated with Janus Kinase Inhibitors
C000224	<b>PO-006</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Time Course and Risk Assessment of Lipid Profile Alterations in Ulcerative Colitis Patients Receiving JAK Inhibitor Therapy: A Real-world Analysis
C000381	<b>PO-007</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CHINESE BIOLOGICS EXPOSURE PATIENTS WITH CROHN’S DISEASE, SUBGROUP RESULTS FROM 2 <sup>ND</sup> INTERIM ANALYSIS OF VALUE STUDY
C000376	<b>PO-008</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CHINESE BIO-NAIVE PATIENTS WITH ULCERATIVE COLITIS, SUBGROUP RESULTS FROM 2 <sup>ND</sup> INTERIM ANALYSIS OF VALUE STUDY
C000246	<b>PO-009</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Short-term effectiveness of continued vedolizumab administration in patients with ulcerative colitis unresponsive to vedolizumab induction therapy
C000281	<b>PO-010</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Generalized Urticaria After Switch Back to Intravenous Vedolizumab Following Injection Site Reactions to Subcutaneous Therapy: A Case Report
C000315	<b>PO-011</b>	Poster Oral Presentation 1	Friday, July 11, 2025	13:00 - 13:45	Room 7	Short term survey of the preference questionnaire of vedolizumab modalities in patients with ulcerative colitis
C000213	<b>PO-012</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Etrasimod efficacy in patients with mildly to moderately active ulcerative colitis (modified Mayo score 4–6) in the phase 3 ELEVATE UC clinical program
C000214	<b>PO-013</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Etrasimod for the treatment of ulcerative colitis: up to 4 years of safety data from the global clinical program
C000212	<b>PO-014</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Pregnancy outcomes in the etrasimod clinical program
C000211	<b>PO-015</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	The impact of etrasimod on the transcriptome in colon biopsies using RNA-seq: data from ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials
C000314	<b>PO-016</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Integrated Long-Term Safety of Ozanimod From Clinical Trials Across 2 Different Indications
C000311	<b>PO-017</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension
C000310	<b>PO-018</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study
C000309	<b>PO-019</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis With Prior Use of 5-Aminosalicylic Acid Only: A Pooled Analysis of True North and J-True North
C000146	<b>PO-020</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Efficacy and Safety of Risankizumab Among Patients in East Asia With Ulcerative Colitis: A Post Hoc Subanalysis of the Randomized Phase 2b/3 INSPIRE and Phase 3 COMMAND Studies
C000333	<b>PO-021</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Efficacy of risankizumab in patients with UST-experienced Crohn's disease.
C000086	<b>PO-022</b>	Poster Oral Presentation 2	Friday, July 11, 2025	13:00 - 13:45	Room 7	Unveiling the Power of Ustekinumab: A Promising Therapy for Crohn's Disease Patients with Symptomatic Intestinal Strictures
C000226	<b>PO-023</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Predictive Factors in the early stage of Carotegrast Methyl treatment for Clinical Remission in Patients with Ulcerative Colitis
C000152	<b>PO-024</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Biologic therapy for the management of budesonide refractory/dependent microscopic colitis
C000223	<b>PO-025</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Long-Term Treatment Persistence, Safety, and Loss of Response to First Anti-Tumor Necrosis Factor (TNF) Therapy in Pediatric and Adolescent Patients with Inflammatory Bowel Disease
C000105	<b>PO-026</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Efficacy and Safety of Different Doses of Adalimumab in Crohn's Disease: A Multicenter Cohort Study in Infliximab-Naïve and Infliximab-Exposed Patients
C000114	<b>PO-027</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Identification of risk factors for disease progression in ulcerative colitis and assessment of biologic treatment based on risk stratification

AOCC2025 - List of Accepted Abstracts (Oral Presentation)


Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000166	<b>PO-028</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Impact of the third lumbar skeletal muscle mass index on drug therapy of patients with inflammatory bowel disease
C000036	<b>PO-029</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Persistence of biologic therapy in patients with inflammatory bowel disease: A single center cohort study
C000342	<b>PO-030</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Clinical and Proteomic Predictors of Primary Response to Infliximab in Crohn’s Disease with Small Bowel Involvement: A Pilot Study in China
C000126	<b>PO-031</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	A study on predicting the efficacy of infliximab for Crohn's disease using pre-treatment endoscopic images.
C000181	<b>PO-032</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	The Efficacy of Upadacitinib in Anti-TNF-Refractory Intestinal Behçet's Disease
C000101	<b>PO-033</b>	Poster Oral Presentation 3	Friday, July 11, 2025	13:00 - 13:45	Room 7	Ustekinumab for Intestinal Behçet's Disease: The First Cohort with a Novel Therapy
C000140	<b>PO-034</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Deep Learning-Based Detection of Crohn’s Disease Lesions in MR Enterography
C000104	<b>PO-035</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Mesenteric and Anti-mesenteric Border Sub-regionalization Using MR Enterography: Advancing Fibrosis Evaluation in Crohn’s Disease
C000057	<b>PO-036</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Artificial Intelligence Based Model for Detecting Ulcers, Polyps, and Erosions Lesions under Endoscopy in Patients with Inflammatory Bowel Disease
C000375	<b>PO-037</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Case series: Can intestinal ultrasound (IUS) reveal the unrevealed in Crohn’s disease?
C000274	<b>PO-038</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	The Application of Intestinal Ultrasound in Assessing Endoscopic and Pathological Activity in Ulcerative Colitis
C000245	<b>PO-039</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Monitoring short-term disease activity using intestinal ultrasonography in patients with ulcerative colitis treated with mirikizumab
C000083	<b>PO-040</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Comparison of Intestinal Ultrasound and Pathological Findings in Patients with Acute Severe Ulcerative Colitis Undergoing Colectomy: A Case Series
C000402	<b>PO-041</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Stereomicroscopic observation for ulcerative colitis-associated neoplasia
C000444	<b>PO-042</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Submucosal Saline Injection and Mini-Probe Endoscopic Ultrasound to Determine the Eligibility of Endoscopic Submucosal Dissection for Ulcerative Colitis-Associated Neoplasia
C000374	<b>PO-043</b>	Poster Oral Presentation 4	Friday, July 11, 2025	13:00 - 13:45	Room 7	Endoscopic ultrasound-guided gastrojejunostomy with a lumen-apposing metal stent for gastric outlet obstruction secondary to Crohn's disease
C000432	<b>PO-044</b>	Poster Oral Presentation 5	Friday, July 11, 2025	13:00 - 13:45	Room 7	Integrating Biomarkers and Advanced Imaging for Non-Invasive Prediction of Crohn's Disease Activity and Clinical Outcomes
C000098	<b>PO-045</b>	Poster Oral Presentation 5	Friday, July 11, 2025	13:00 - 13:45	Room 7	Evaluation of the relationship between clinical and endoscopic disease activity and serum uric acid levels in inflammatory bowel disease in a Japanese population
C000071	<b>PO-046</b>	Poster Oral Presentation 5	Friday, July 11, 2025	13:00 - 13:45	Room 7	Peripheral blood neutrophil activity as a novel biomarker in patients with ulcerative colitis
C000385	<b>PO-047</b>	Poster Oral Presentation 5	Friday, July 11, 2025	13:00 - 13:45	Room 7	miRNAs as Prognostic Tools for Predicting Biologic Therapy Response in IBD Patients
C000216	<b>PO-048</b>	Poster Oral Presentation 5	Friday, July 11, 2025	13:00 - 13:45	Room 7	Optimizing Endoscopic Activity Prediction For Inflammatory Bowel Disease Patients By Using Blood Sample Tests
C000121	<b>PO-049</b>	Poster Oral Presentation 5	Friday, July 11, 2025	13:00 - 13:45	Room 7	Exploring the Value of Fecal Calprotectin in Crohn’s Disease
C000043	<b>PO-050</b>	Poster Oral Presentation 5	Friday, July 11, 2025	13:00 - 13:45	Room 7	Fecal Calprotectin, Fecal Immunochemical Test, and Their Combination for Predicting Endoscopic and Histologic Remission in Clinically Quiescent Ulcerative Colitis
C000390	<b>PO-051</b>	Poster Oral Presentation 5	Friday, July 11, 2025	13:00 - 13:45	Room 7	DEVELOPMENT OF CROHN'S AID MOBILE APPLICATION BASED ON AI ALGORITHMS TO MAKE AN EARLY DIAGNOSIS OF CROHNS DISEASE IN TB ENDEMIC REGIONS
C000241	<b>PO-052</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	Usefulness of Intraoperative Endoscopy in Crohn's Disease Intestinal Resection
C000268	<b>PO-053</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	Pharmacological Strategies for Preventing Postoperative Recurrence in Crohn’s Disease: a systematic review and network meta-analysis of randomized controlled trials
C000350	<b>PO-054</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	Efficacy and predictive factors for response to Teduglutide in short bowel syndrome caused by Crohn’s Disease
C000286	<b>PO-055</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	L4a CD Patients Exhibit a Higher Incidence of Surgery within 1 Year Post-Diagnosis: A Single-Center Retrospective Analysis
C000148	<b>PO-056</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	Safety and Efficacy of Intralesional Administration of TH-SC01 Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Perianal Fistula in Crohn's Disease: Phase 1 and 2 Clinical Trials

AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000266	<b>PO-057</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	Effectiveness of exclusive enteral nutrition for adult patients with perianal fistulizing Crohn's disease: a real-world study
C000348	<b>PO-058</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	Impact of History of Cytomegalovirus Infection on Patients with Ulcerative Colitis
C000351	<b>PO-059</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	Treatment Strategy After Cyclosporine-Induced Remission for Acute Severe Ulcerative Colitis: Mid-term Outcomes
C000428	<b>PO-060</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	Safety and efficacy of combination therapy with tacrolimus and biologics in ulcerative colitis.
C000340	<b>PO-061</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	A Randomized, Controlled, Multicenter Clinical Trial of Yuyang Powder for Mild to Moderate Active Ulcerative Colitis
C000030	<b>PO-062</b>	Poster Oral Presentation 6	Friday, July 11, 2025	13:00 - 13:45	Room 7	An exploratory clinical study to evaluate the safety and efficacy of Centella asiatica in ulcerative colitis
C000267	<b>PO-063</b>	Poster Oral Presentation 7	Friday, July 11, 2025	13:00 - 13:45	Room 7	Familial vs. Sporadic Crohn's Disease in China: A Multicenter Retrospective Cohort Analysis Over a Decade
C000312	<b>PO-064</b>	Poster Oral Presentation 7	Friday, July 11, 2025	13:00 - 13:45	Room 7	The correlation between Helicobacter pylori infection and iron deficiency in adults with inflammatory bowel disease in Taiwan
C000197	<b>PO-065</b>	Poster Oral Presentation 7	Friday, July 11, 2025	13:00 - 13:45	Room 7	Increased risk of venous thromboembolism post hospital discharge in patients with inflammatory bowel disease: a systematic review and meta-analysis
C000106	<b>PO-066</b>	Poster Oral Presentation 7	Friday, July 11, 2025	13:00 - 13:45	Room 7	The Impact of Crohn's Disease on Fertility in Chinese Women: A Comparative Study with the General Population
C000094	<b>PO-067</b>	Poster Oral Presentation 7	Friday, July 11, 2025	13:00 - 13:45	Room 7	Comparative Risk of Chronic Kidney Disease Between Autoimmune Diseases and Inflammatory Bowel Diseases
C000279	<b>PO-068</b>	Poster Oral Presentation 7	Friday, July 11, 2025	13:00 - 13:45	Room 7	EXTRAINTESTINAL MANIFESTATIONS IN ULCERATIVE COLITIS PATIENTS WITH DISEASE PHENOTYPE: INSIGHTS FROM A PAKISTANI COHORT
C000091	<b>PO-069</b>	Poster Oral Presentation 7	Friday, July 11, 2025	13:00 - 13:45	Room 7	Efficacy of Upadacitinib in Moderate-Severe Active Ulcerative Colitis, Hope or Hype? : A Systematic Review & Meta Analysis of Randomized Clinical Trials
C000027	<b>PO-070</b>	Poster Oral Presentation 7	Friday, July 11, 2025	13:00 - 13:45	Room 7	Analysis of clinical features of IL-17 inhibitor-associated inflammatory bowel disease and systemic review
C000042	<b>PO-071</b>	Poster Oral Presentation 8	Friday, July 11, 2025	13:00 - 13:45	Room 7	Self-perception of disease phenotype in patients with mild to moderate ulcerative colitis - a nationwide survey
C000225	<b>PO-072</b>	Poster Oral Presentation 8	Friday, July 11, 2025	13:00 - 13:45	Room 7	Questionnaire survey of Japanese patients with IBD and physicians on shared decision making in advanced therapy : A web-based PAIR survey
C000088	<b>PO-073</b>	Poster Oral Presentation 8	Friday, July 11, 2025	13:00 - 13:45	Room 7	The Association of Anxiety and Depression with the Quality of Life of Inflammatory Bowel Disease Patients
C000165	<b>PO-074</b>	Poster Oral Presentation 8	Friday, July 11, 2025	13:00 - 13:45	Room 7	The influence of anxiety and depression and the online mindfulness interventions on the quality of life among patients with Inflammatory Bowel Disease (IBD) : Web-Based Survey Study
C000304	<b>PO-075</b>	Poster Oral Presentation 8	Friday, July 11, 2025	13:00 - 13:45	Room 7	Risk Factors and Prognostic Impact of Depression in Inflammatory Bowel Disease: A Prospective Cohort Study
C000116	<b>PO-076</b>	Poster Oral Presentation 8	Friday, July 11, 2025	13:00 - 13:45	Room 7	Cognitive Assessment Regarding Premedication Before Intravenous Administration of Infliximab Among IBD Specialists
C000046	<b>PO-077</b>	Poster Oral Presentation 8	Friday, July 11, 2025	13:00 - 13:45	Room 7	Concerns and Challenges Related to Sexual Well-Being in Patients with Inflammatory Bowel Disease: Insights from Nurse Interviews
C000016	<b>PO-078</b>	Poster Oral Presentation 8	Friday, July 11, 2025	13:00 - 13:45	Room 7	Telehealth by IBD nurses in a tertiary IBD center in China
C000420	<b>PO-079</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	A case of atypical familial mediterranean fever in a patient with ulcerative colitis
C000414	<b>PO-080</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	Rectal Mucosal Prolapse Syndrome : A Disease Mimicking Inflammatory Bowel Disease
C000230	<b>PO-081</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	Multigenic Mutations Underlying Recurrent Abdominal Pain, Constipation, and Refractory Atopic Dermatitis: A Case Study Integrating Genetic and Clinical Perspectives
C000416	<b>PO-082</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	An Unusual Case of Gastrointestinal Bleeding with Abdominal Pain and Purpura
C000011	<b>PO-083</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	Unusual Pseudo-Obstruction: A Diagnostic Challenge
C000418	<b>PO-084</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	Owl's Eye: A Rare Presentation of CMV Colitis in Patient Treated with Tofacitinib.
C000018	<b>PO-085</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	A case of cytomegalovirus colitis and clostridioides difficile infection after one month of oral steroid therapy in a healthy individual
C000394	<b>PO-086</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	Successful treatment of Crohn's disease complicated by Takayasu's arteritis with adalimumab: A case report



AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000322	<b>PO-087</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	DISSEMINATED HISTOPLASMOSIS AFTER USTEKINUMAB TREATMENT: SAFE, BUT IS IT THE SAFEST?
C000103	<b>PO-088</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	Clinical Differentiation Between Hereditary Angioedema and Inflammatory Bowel Disease: A Case Report and Literature Review
C000231	<b>PO-089</b>	Poster Oral Presentation 9	Friday, July 11, 2025	13:00 - 13:45	Room 7	Management Challenges and Multidisciplinary Approach in Adult Autoimmune Enteropathy with Severe Malnutrition: A Case Report
C000326	<b>PO-090</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	Multi-ethnic Asian Inflammatory Bowel Disease Multi-omic Study (ILETIS) - Study Protocol and Pilot Findings
C000206	<b>PO-091</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	Psychosine confines Th1 and Th17 cell proliferation and immune responses in inflammatory bowel diseases
C000331	<b>PO-092</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	From Fibroblast Heterogeneity to Pro-Fibroblast Crosstalk: A Single-Cell Atlas of Crohn’s Disease-Associated Anorectal Stricture
C000401	<b>PO-093</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	Investigating the Role of Ubiquitination in the Pathogenesis of Crohn's Disease: Insights from Single-Cell Analysis
C000265	<b>PO-094</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	Immune Signatures of Mesalazine Intolerance in Patients with Ulcerative Colitis using RNA Sequencing of CD4+ T Cells.
C000167	<b>PO-095</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	Qingchang Suppository Promotes Mucosal Healing in Ulcerative Colitis Through the TGF- $\beta$ /Th9-PU.1/IL-9 Signaling Pathway: From Clinical to Cellular Scenarios
C000055	<b>PO-096</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	Qingchang Suppository Promotes Intestinal Mucosal Repair in Ulcerative Colitis by Inhibiting TGF-b/Th9-PU.1/IL-9 Signaling Pathway
C000128	<b>PO-097</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	ADAMDEC1 <sup>+</sup> EREG <sup>+</sup> FIBROBLAST DRIVES THE PERSISTENCE OF CHRONIC INFLAMMATION VIA INTERACTIONS WITH IL1RN <sup>+</sup> MACROPHAGEIN CROHN'S DISEASE
C000434	<b>PO-098</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	PCDH20 regulates pro-inflammatory Th1 cells in Crohn's disease
C000150	<b>PO-099</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	The Role of Malic Enzyme 1 in Macrophage Pyroptosis and Inflammatory Bowel Disease Progression
C000415	<b>PO-100</b>	Poster Oral Presentation 10	Friday, July 11, 2025	13:00 - 13:45	Room 7	BMPR2-F456Y Mutation Causes Hirschsprung Disease via Protein Destabilization and SMAD Signaling Impairment
C000423	<b>PO-101</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	Dual-Source DPP4 Drives Intestinal Fibrosis in Crohn’s Disease: Synergistic Therapeutic Targeting of Host and Microbiota Pathways
C000440	<b>PO-102</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	Smoking Status and Akkermansia muciniphila : Mendelian Randomization Study
C000076	<b>PO-103</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	Engineering TNF- $\alpha$ -modulating probiotics for effective treatment of inflammatory bowel disease
C000108	<b>PO-104</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	Salivary Veillonella parvula from Crohn's Disease Patients Exacerbates Intestinal Inflammation
C000032	<b>PO-105</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	Pancreatic Glycoprotein 2: A Mucosal Defense Regulating Bacterial Translocation in IBD
C000349	<b>PO-106</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	Impact of Mucosal Inflammation on Microbial Migration Across the Intestinal Mucus Barrier in Inflammatory Bowel Disease
C000021	<b>PO-107</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	Therapeutic Potential of Anti-Mature IL-18 monoclonal Antibody for Inflammatory Bowel Disease
C000247	<b>PO-108</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	PARD6B regulates host-microbe crosstalk via Paneth cell homeostasis and Goblet cell function
C000269	<b>PO-109</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	Regulation of Bile Acid Metabolism via 7-HDSH Conversion by Clostridium scindens Modulates Colonic Inflammation and Mucosal Healing
C000164	<b>PO-110</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	The Role and Mechanism of Ephrin B2 in Crohn's Disease-Associated Intestinal Fibrosis
C000242	<b>PO-111</b>	Poster Oral Presentation 11	Friday, July 11, 2025	13:00 - 13:45	Room 7	The therapeutic effect and mechanism of Bu yang Huan wu Tang(BHT) on DSS-induced intestinal fibrosis in IBD mice via inhibiting the Wnt/ $\beta$ -catenin pathway
C000426	<b>PO-112</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	Susceptibility gene MFSD12-variant drives intestinal inflammation via mTORC1-ATOH8-SFRP1 axis in CD4 <sup>+</sup> T cells
C000229	<b>PO-113</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	The susceptibility gene MFSD12 variation exacerbates colitis through SPRAC-mediated macrophage repolarization
C000119	<b>PO-114</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	Systemic Deletion of DUOX2 Protect Mice from DSS-induced Intestinal Inflammation
C000147	<b>PO-115</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	Epithelial MST1 deficiency promotes pyroptosis and aggravates inflammatory bowel disease via the YAP/p73 signaling pathway
C000176	<b>PO-116</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	L-Type Amino Acid Transporter 1 Plays a Key Role in Tissue Repair in DSS-Induced Colitis
C000264	<b>PO-117</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	Piezo1-Mediated Lactate Metabolism via HIF-1 $\alpha$ -MCT1 Axis Exacerbates Intestinal Inflammation in IBD

AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000343	<b>PO-118</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	Inhibition of CIRP Nuclear Export Modulates the mtDNA-Driven PANoptosis Axis to Attenuate Colonic Mucosal Damage in Ulcerative Colitis
C000439	<b>PO-119</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	Research on the Expression of Phosphodiesterase 4B in Inflammatory Bowel Disease and Its Mechanism of Regulating Intestinal Inflammation
C000163	<b>PO-120</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	S-equol, a metabolite of dietary soy isoflavones, alleviates DSS-induced colitis in mice through binding to Er $\beta$
C000235	<b>PO-121</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	Exploring the Effects and Mechanisms of Sanren Tang in Ulcerative Colitis Mice via Modulation of the B-Cell Receptor Signaling Pathway
C000273	<b>PO-122</b>	Poster Oral Presentation 12	Friday, July 11, 2025	13:00 - 13:45	Room 7	Kushenol A reprograms PPAR $\gamma$ signaling-mediated lipid metabolism of macrophages to attenuate colitis
C000001	<b>PE-001</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Clinicopathological study of primary small bowel malignant tumors: A single institute experience in Taiwan
C000003	<b>PE-002</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Whole-exome sequencing for identifying three novel susceptible genetic loci in Korean patients with inflammatory bowel disease
C000007	<b>PE-003</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Effectiveness of adjunctive use of antibiotics in acute severe ulcerative colitis
C000015	<b>PE-004</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Re-bleeding risk associated with catheter angiography and colonoscopy following a positive computed tomography angiography in patients experiencing severe lower gastrointestinal bleeding
C000022	<b>PE-005</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Transient elastography with controlled attenuation parameter for the evaluation of hepatic fibrosis in a prospective cohort of inflammatory bowel disease patients
C000028	<b>PE-006</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Difference in Immune Profiling According to the Metabolic Dysfunction-Associated Steatotic Liver Disease in Ulcerative Colitis Patients
C000029	<b>PE-007</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Clinical implication of nonalcoholic fatty liver disease in ulcerative colitis patients
C000033	<b>PE-008</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Short- and long-term outcome of endoscopic resection for serrated polyps in patients with ulcerative colitis
C000034	<b>PE-009</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Advanced therapy in patients with ulcerative colitis and malignant disease: A case study
C000035	<b>PE-010</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Inflammatory Bowel Disease Patients need Higher Opioid Analgesic for Intravenous Conscious Sedation for Colonoscopy.
C000039	<b>PE-011</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Comparison of clinical characteristics of Montreal classification group A3 patients with Crohn’s disease in Korea: Results from the Prospective and Retrospective CONNECT Study,
C000040	<b>PE-012</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Segmental Mucosal Microbiome Variations Across Different Inflammation Extents in Ulcerative Colitis
C000044	<b>PE-013</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Risk Factors of Extraintestinal Manifestations in IBD
C000045	<b>PE-014</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Impacts of Serum Microelements on Disease Activity in Patients with Inflammatory Bowel Disease on Asian Population-Based Study
C000047	<b>PE-015</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Prevalence and Association Between Antinuclear Antibodies and Inflammatory Bowel Disease in Taiwan
C000052	<b>PE-016</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Surveillance of Hepatitis B and C Serological Status in Inflammatory Bowel Disease Patients: A Single Hospital Data
C000058	<b>PE-017</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Ulcerative Colitis with Pyoderma Gangrenosum
C000059	<b>PE-018</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Treating Ulcerative Colitis Flare-Ups During Postpartum Lactation with Vedolizumab
C000061	<b>PE-019</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	A Case of Allergy to Upadacitinib in Ulcerative Colitis
C000069	<b>PE-020</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Effect of Modified Traditional Jiangnan Diet (MTJD) in Patients with Crohn’s Disease: a Pilot, Open-label, Randomized Clinical Trial
C000075	<b>PE-021</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Ulcerative Colitis Disease Activity During Surveillance Endoscopy in a Single Medical Center
C000077	<b>PE-022</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Emergence of a novel macrophage population during intestinal inflammation and fibrosis
C000078	<b>PE-023</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Case Report of Glucocorticoid Combined With Sequential Stages of Chinese Medicine Treatment on Severe Ulcerative Colitis
C000082	<b>PE-024</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Unveiling Mesenteric and Intestinal Changes in Crohn’s Disease: Insights into Fibrosis from Surgical Specimens
C000084	<b>PE-025</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Real-world Experience With Janus Kinase Inhibitors (JAKis) In Patients With Inflammatory Bowel Disease (IBD) – A Multi-Centre Experience From Singapore
C000087	<b>PE-026</b>	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Risk Factors and Awareness of Bone fragility in Inflammatory Bowel Disease in Taiwan: A Cross-Sectional Study

AOCC2025 - List of Accepted Abstracts (Oral Presentation)


Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000092	PE-027	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Aeromonas hydrophila Colitis Mimicking Ulcerative Colitis in an Adolescent Male
C000093	PE-028	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Treat to Target Strategy In IBD: A Real World Multicentre Experience In Singapore
C000096	PE-029	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	You will be forcibly logged out, if you leave this page for 60 minutes. If you want to interrupt the abstract submission, click the "Save and Continue" button to save it.
C000097	PE-030	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Safety of the Adjuvant Recombinant Herpes Zoster Vaccine in Crohn's Disease and Ulcerative Colitis: A Real-World Study
C000099	PE-031	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Comparative Study on the Efficacy of Biologics with Dietary Intervention in Crohn's Disease: Evaluating the Impact of Crohn's Disease Exclusion Diet and partial Entral nutrition Combination with Biologics
C000112	PE-032	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Characterization of the phage of Japanese patients with ulcerative colitis
C000113	PE-033	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Challenges in Accessing Biologics for IBD in Taiwan: A Study of NHI Reimbursement Rejections In a Medical Center
C000115	PE-034	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Barriers and Perceptions of Zoster Vaccination Among Patients with Inflammatory Bowel Disease: A Cross-Sectional Survey Study
C000117	PE-035	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	High cholesterol diet promotes the development and progression of IBD-associated colorectal cancer by increasing the inflammatory cytokines and oxydized derivatives of cholesterol
C000120	PE-036	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	The role of immunosuppressant agent in the era of non-anti-TNF biologics for inflammatory bowel disease
C000122	PE-037	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Analysis of the intestinal microbiome </strong><strong>using an endoscopic brush in Ulcerative colitis
C000123	PE-038	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Oral and Gut Microbiome Analysis in Korean Patients with Crohn's Disease
C000124	PE-039	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Factors influencing the discontinuation of biologic therapies in patients with inflammatory bowel disease
C000130	PE-040	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	A Retrospective Cross-sectional Study of Clinical Characteristics and Treatment Differences in Elderly and Adults onset Ulcerative Colitis disease
C000133	PE-041	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Comparative Transcriptomic Analysis of Tonsil-derived and Adipose-derived Mesenchymal Stem Cells: Proliferation, Migration, and Anti-inflammatory Potential in Murine Colitis Model
C000134	PE-042	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	DIFFERENTIAL EFFICACY OF ADVANCED THERAPIES BY DISEASE LOCATION IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
C000135	PE-043	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	A rare case of rapid growth large diffuse B-cell lymphoma in ulcerative colitis with long-term remission
C000138	PE-044	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Safety and Adverse Events of the Adjuvanted Herpes Zoster Vaccine (Shingrix) in Inflammatory Bowel Disease Patients: A Comparison of Age Groups Under and Over 50 Years
C000145	PE-045	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Fecal Calprotectin as a Potential Biomarker for Depression: A Systematic Review and Meta-Analysis
C000151	PE-046	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Thromboembolic Risk of Upadacitinib in Inflammatory Bowel Disease: A Real-World Pharmacovigilance Analysis of Timing, Subtypes, and High-Risk Populations
C000153	PE-047	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Temporal Changes of Gut Microbiota and Micro-RNAs according to Disease Activity in Chronic Colitis
C000154	PE-048	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Leucine-rich alpha-2 glycoprotein as a valuable biomarker for detecting small bowel lesions in Crohn's disease
C000156	PE-049	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Comparison of Ustekinumab and Vedolizumab for Moderate to Severe Ulcerative Colitis Following Prior Failure of Biologics or Small Molecule Drugs
C000159	PE-050	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Factors associated with urgent consultation recommendations for patients with inflammatory bowel disease calling a telephone service about worsening symptoms: a secondary analysis
C000168	PE-051	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Clinical Usefulness of Fecal Calprotectin in Assessing Disease Activity and Mucosal Healing in Intestinal Behçet's Disease
C000170	PE-052	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	A National Survey and Analysis of Treatment Goals for Inflammatory Bowel Disease Among Gastroenterologists in China
C000171	PE-053	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Exacerbation of Previously Undetected Ulcerative Colitis in a Patient Undergoing Nivolumab for Metastatic Melanoma
C000173	PE-054	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Incidence of Hepatitis A and Hepatitis C in Patients with Inflammatory Bowel Disease in Korea



AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000177	PE-055	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Upadacitinib for the Treatment of Ulcerative Colitis: A Single-Center Study in North China
C000178	PE-056	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Perceptions and Clinical Practices Regarding the Interrelation of Inflammatory Bowel Disease and Metabolic Disorders: An International Survey Study
C000179	PE-057	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Clinical Impact of Withholding Oral Intake in Acute Severe Ulcerative Colitis: A Single-Center Retrospective Study
C000180	PE-058	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Evaluating Outcomes Based on Endoscopic and Histological Inflammatory Activity in Patients with Ulcerative Colitis
C000189	PE-059	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Guselkumab efficacy and safety in East Asian participants with moderate to severely active Crohn's disease: Subgroup analysis of the GALAXI-2 and GALAXI-3 Phase 3 studies
C000190	PE-060	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: Subgroup analysis of the Phase 3 GRAVITI study
C000191	PE-061	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Guselkumab efficacy and safety in East Asian participants with moderate to severely active ulcerative colitis: Subgroup analysis of the Phase 2b/3 QUASAR induction and maintenance studies
C000199	PE-062	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	The biologics containing citrate deteriorate the willingness to continue treatment
C000200	PE-063	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	The Clinical Features of Obese Crohn's disease in Patients
C000203	PE-064	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Co-Infection of Clostridium difficile and Cytomegalovirus in First Presentation of Crohn's Colitis in an Elderly Patient
C000204	PE-065	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Tofacitinib, rescue therapy for Infliximab-experienced patients with acute severe ulcerative colitis: A single centre experience
C000205	PE-066	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Comparative Drug Survival of Anti-TNF Agents and Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience in Taiwan
C000208	PE-067	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	CEPT1 Promote the Development of Mesenteric Adipose Tissue Fibrosis by Inhibiting Phosphatidylethanolamine Formation in DPP4+CCL2+ Mesenchymal Stem Cells
C000209	PE-068	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Current Status of Medical Care for Elderly Patients with Ulcerative Colitis at Our Hospital
C000215	PE-069	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Changes in serum bile acid composition in patients with inflammatory bowel disease
C000219	PE-070	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	The Association between serum zinc levels and tight junction proteins in the intestinal mucosal epithelium in patients with inflammatory bowel disease.
C000221	PE-071	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Optimal timing and predictors of treatment response to intravenous corticosteroids therapy in hospitalized patients with ulcerative colitis
C000222	PE-072	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	The impact of extraintestinal manifestations on disease courses in newly diagnosed patients with inflammatory bowel diseases
C000228	PE-073	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Seasonal variation in Crohn's disease relapse: An ad-hoc analysis of a cohort of patients maintaining remission on receiving biologics
C000233	PE-074	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Evaluation of clinical activity index and biomarkers in predicting therapeutic efficacy of IL-12/23 inhibitors in patients with moderate to severe ulcerative colitis
C000234	PE-075	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Long-Term Health Outcomes in Offspring of Women with Inflammatory Bowel Disease: A Nationwide Study
C000244	PE-076	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	A Real-World Adverse Events in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Nationwide Population-based Cohort Study in South Korea
C000249	PE-077	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	FIVE-YEAR CLINICAL OUTCOMES AND DISEASE COURSE OF NEWLY-DIAGNOSED MODERATE-TO-SEVERE ULCERATIVE COLITIS: A PROSPECTIVE NATIONWIDE MULTICENTER MOSAIK COHORT STUDY IN KOREA
C000252	PE-078	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Etiology and Differential Diagnosis of Terminal Ileum Lesions with Symptoms: A Retrospective Study of 224 Patients
C000254	PE-079	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Pregnancy and Neonatal Outcomes After Fetal Exposure to Thiopurines Among Asian Women With Inflammatory Bowel Disease
C000255	PE-080	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Clinical Features and Treatment in Korean Patients with Gastrointestinal Behçet's Disease: A Retrospective Study of 327 Patients
C000257	PE-081	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	RESULTS OF THE SURGICAL TREATMENT OF ULCERATIVE COLITIS
C000271	PE-082	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Comparison of the prevalence and characteristics of biliary diseases in ulcerative colitis and Crohn's disease.

AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000272	PE-083	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Therapeutic drug monitoring and efficacy evaluation of vedolizumab in patients with inflammatory bowel disease
C000280	PE-084	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Deep Learning Model Utilizing Stool Images to Differentiate Ulcerative Colitis from Irritable Bowel Syndrome and Healthy Controls
C000282	PE-085	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	A Decade-Long Follow-up Study of Korean IBD Patients: Differences by Age at Diagnosis
C000287	PE-086	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Efficacy of upadacitinib to treat acute severe ulcerative colitis
C000295	PE-087	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Considering Longitudinal Changes and Patient Heterogeneity Improves Gut Microbiome Signatures for Predicting Adalimumab Efficacy in UC
C000296	PE-088	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Paradoxical onset of vasculitic diseases in patients with ulcerative colitis(UC) treated with anti-tumor necrosis factor(TNF)- $\alpha$ antibodies
C000297	PE-089	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	CHARACTERIZATION OF PHARMACOKINETICS OF GUSELKUMAB IN CHINESE CROHN’S DISEASE PATIENTS: GALAXI 2 AND 3 SUBGROUP ANALYSIS
C000298	PE-090	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	EFFICACY OF GUSELKUMAB IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE ACCORDING TO CLINICAL RESPONSE AT INDUCTION: SUBGROUP ANALYSIS OF THE PHASE 3 GALAXI 2 AND 3 STUDIES
C000299	PE-091	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	EFFECT OF GUSELKUMAB VERSUS USTEKINUMAB ON BIOMARKERS IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: SUBGROUP ANALYSIS OF THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 GALAXI 2 AND 3 STUDIES
C000300	PE-092	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	EFFICACY OF GUSELKUMAB VERSUS PLACEBO BASED ON PRIOR EXPOSURE TO BIOLOGIC THERAPY IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: SUBGROUP ANALYSIS OF GALAXI 2 and 3 STUDIES
C000301	PE-093	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Chinese Patients With Moderately to Severely Active Ulcerative Colitis: Subgroup Analysis of the Phase 3 QUASAR Maintenance Study
C000305	PE-094	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Clinical profile of adverse events caused by immunomodulator in ulcerative colitis
C000306	PE-095	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Structural and Functional Characteristics of Oral and Gut Microbiome of Perianal Fistulizing Crohn's Disease Patients
C000307	PE-096	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Correlation Between Ultrasonographic Response and Ustekinumab Drug Levels in Crohn’s disease
C000316	PE-097	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Longitudinal analysis of changes in gut microbiota and microRNA expression between active and remission phases in patients with ulcerative colitis
C000317	PE-098	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Correlations between the Simple Endoscopic Score for Crohn’s Disease and fecal calprotectin in pediatric patients with Crohn’s disease
C000324	PE-099	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Treatment Experience of Patients with Inflammatory Bowel Disease Using Biologic Agents/Janus Kinase Inhibitors
C000325	PE-100	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	$\alpha$ -Linolenic Acid Metabolism as a Shared Pathway in Inflammatory Bowel Disease and Depression: Insights from Bioinformatic Analysis
C000327	PE-101	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	A rare case of tuberos pericarditis in a patient treated with advanced therapy for Crohn’s disease and ankylosing spondylitis
C000328	PE-102	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Porphyromonas gingivalis aggravates Inflammatory bowel disease via outer membrane vesicles
C000329	PE-103	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Periodontitis exacerbates colitis via oral pathogen-induced epithelial extracellular vesicles
C000332	PE-104	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Factors associated with incomplete patency of capsule endoscopy in postoperative Crohn's disease patients: a sub-analysis of the J-PROSPECT study.
C000337	PE-105	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Guselkumab efficacy and safety in East Asian participants with moderate to severely active ulcerative colitis: Subgroup analysis of the Phase 3 ASTRO subcutaneous induction and maintenance studies
C000338	PE-106	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Evaluating the Impact of a Nurse-led Telephone Advice Service on IBD Patient Care at Tan Tock Seng Hospital
C000355	PE-107	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Real-World Efficacy and Safety of Filgotinib in Elderly and Elderly-Onset Ulcerative Colitis: A Retrospective Study
C000361	PE-108	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Dietary Acceptance of Crohn’s Disease Exclusion Diet (CDED) Among IBD Patients In Malaysia: A Qualitative Study
C000378	PE-109	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Neonatal Fc Receptor-Mediated Mechanisms in IBD Pathophysiology and Therapeutic Applications
C000379	PE-110	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Real-world evidence of recapturing clinical remission with subcutaneous infliximab after switching from intravenous therapy in patients with ulcerative colitis: A 2-year multicenter prospective study in Korea



AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000380	PE-111	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Mental Health and Quality of Life in Asian IBD Patients: A Cross-Sectional Study at a Tertiary Hospital in Singapore
C000382	PE-112	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Deep Learning-Driven Crypt-Fate Decision Model Predicts Mesenchymal-Like Transitions in Crohn’s Disease Using AI-Based Spatial Epigenetic Remodeling of Intestinal Stem Cell Niches
C000383	PE-113	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	AI-Driven Multi-Omics Model Predicts Crypt Stem Cell Dysfunction and Fibrotic Remodeling in Crohn’s Disease
C000384	PE-114	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Multi-Resolution Deep Learning Identifies Hidden Epigenetic Predictors of Crohn’s Disease Penetrance and Treatment Resistance Using Single-Cell Multi-Omics Integration
C000386	PE-115	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Extremely high prevalence of multidrug-resistant organisms in gut flora of hospitalised patients with gastro-intestinal illness
C000387	PE-116	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Deep Learning-Driven Multi-Omics Model for Personalized Anti-TNF Response Prediction in Crohn’s Disease
C000388	PE-117	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Deep Learning-Driven Predictive Model for Early Identification of Fibrostenotic Progression in Crohn’s Disease: Integrating Spatial Transcriptomics, Single-Cell Multi-Omics, and Temporal Graph Learning
C000391	PE-118	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Effectiveness of switching from intravenous to subcutaneous infliximab in patients with Perianal Fistulizing Crohn’s Disease
C000393	PE-119	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Tight endoscopic surveillance for the Treatment of Dysplasia in ulcerative colitis
C000398	PE-120	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Evaluating the efficacy of tonsil-derived mesenchymal stem cells and intestinal stem cells- like cells in modulating fibrosis and inflammation in murine colitis models
C000399	PE-121	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Factors associated with discontinuation of biologics or small molecules in patients with inflammatory bowel disease
C000406	PE-122	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	ABO blood type and clinical characteristics of patients with ulcerative colitis at the First Central hospital of Mongolia
C000409	PE-123	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Ustekinumab-Induced Hypophysitis in a Patient with Refractory Crohn’s Disease: A Rare Case of Secondary Adrenal Insufficiency
C000412	PE-124	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Clinical Feature Analysis of Inflammatory Bowel Disease Complicated with Primary Sclerosing Cholangitis
C000422	PE-125	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Long-term Real-world Efficacy and Safety of Tofacitinib for Ulcerative Colitis: A Five-year Retrospective Study
C000425	PE-126	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Mapping the Landscape of Endoscopic Balloon Dilation in IBD: A Bibliometric Perspective
C000429	PE-127	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Microbiome Diversity and Taxonomic Differences in Quiescent Ulcerative Colitis: A Comparative Study of Proximal Extension
C000435	PE-128	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	The Role of CALLY Index in Disease Assessment and Prognosis of Active Ulcerative Colitis
C000445	PE-129	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Beyond Conventional therapy targeting multiple pathways: Combination Tofacitinib-Ustekinumab in Refractory Crohn's disease
C000446	PE-130	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	EFFICACY AND SAFETY OF GUSELKUMAB FOR ULCERATIVE COLITIS THROUGH WEEK 92 OF THE QUASAR LONG-TERM EXTENSION STUDY
C000447	PE-131	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative colitis: Results through week 12 from the phase 3 ASTRO study
C000155	PE-132	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Impact of Small Area Level Deprivation on Colorectal Cancer Survival: Findings from the Regional Cancer Registry in Korea
C000157	PE-133	Poster Exhibition	July 11-12, 2025	All Day	Room 8~10	Comparison of Clinical Outcomes Between Planned Piecemeal Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection for Neoplasms Involving the Appendiceal Orifice and Lumen